Axsome Therapeutics, which is developing novel therapies for pain and CNS disorders utilizing the 505(b)(2) pathway, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering.
The company cites 2015 IPOs Carbylan Therapeutics (CBYL) and Flexion Therapeutics (FLXN) as potential competitors.
The New York, NY-based company, which was founded in 2012, plans to list on the Nasdaq under the symbol AXSM. Axsome Therapeutics initially filed confidentially on August 25, 2015. Ladenburg Thalmann is the sole bookrunner on the deal. No pricing terms were disclosed.
